Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.

Literature DB >> 6097169

Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.

S C Aronoff, M R Jacobs, S Johenning, S Yamabe.

Abstract

YTR 830, a new beta-lactamase inhibitor, was compared with clavulanic acid and sulbactam against aminopenicillin-resistant clinical isolates. At a concentration of 8 micrograms/ml, YTR 830 was as effective as clavulanate or sulbactam in reducing the aminopenicillin MICs. Combined with amoxicillin, YTR 830 is a potentially useful agent for therapy of many bacterial infections.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1984 PMID： 6097169 PMCID： PMC179968 DOI： 10.1128/AAC.26.4.580

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

2 in total

Review 1. The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics.

Authors: R B Sykes; M Matthew
Journal: J Antimicrob Chemother Date: 1976-06 Impact factor: 5.790

2. Plasmid-determined beta-lactamases identified in a group of 204 ampicillin-resistant Enterobacteriaceae.

Authors: C Roy; A Foz; C Segura; M Tirado; C Fuster; R Reig
Journal: J Antimicrob Chemother Date: 1983-11 Impact factor: 5.790

2 in total

45 in total

1. Comparison of ampicillin/sulbactam and amoxicillin/clavulanic acid for detection of borderline oxacillin-resistant Staphylococcus aureus.

Authors: H Liu; N Lewis
Journal: Eur J Clin Microbiol Infect Dis Date: 1992-01 Impact factor: 3.267

2. Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli.

Authors: W Kern; S L Kennedy; M Sachdeva; E R Sande; D Gunderson; M G Täuber
Journal: Antimicrob Agents Chemother Date: 1990-05 Impact factor: 5.191

3. Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam.

Authors: F Moosdeen; J D Williams; S Yamabe
Journal: Antimicrob Agents Chemother Date: 1988-06 Impact factor: 5.191

4. Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.

Authors: L Gutmann; M D Kitzis; S Yamabe; J F Acar
Journal: Antimicrob Agents Chemother Date: 1986-05 Impact factor: 5.191

5. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).

Authors: A Bauernfeind; S Schweighart; E Eberlein; R Jungwirth
Journal: Infection Date: 1991 Impact factor: 3.553

6. Comparative efficacies of amoxicillin-clavulanic acid and ampicillin-sulbactam against experimental Bacteroides fragilis-Escherichia coli mixed infections.

Authors: J Gisby; A S Beale
Journal: Antimicrob Agents Chemother Date: 1988-12 Impact factor: 5.191

Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.

Review 1. The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics.

2. Plasmid-determined beta-lactamases identified in a group of 204 ampicillin-resistant Enterobacteriaceae.

1. Comparison of ampicillin/sulbactam and amoxicillin/clavulanic acid for detection of borderline oxacillin-resistant Staphylococcus aureus.

2. Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli.

3. Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam.

4. Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.

5. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).

6. Comparative efficacies of amoxicillin-clavulanic acid and ampicillin-sulbactam against experimental Bacteroides fragilis-Escherichia coli mixed infections.

7. In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations.

8. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.

9. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.

Review 10. Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy.